Zacks: Trevi Therapeutics Inc (NASDAQ:TRVI) Given $16.75 Average Price Target by Brokerages
Shares of Trevi Therapeutics Inc (NASDAQ:TRVI) have received an average broker rating score of 1.25 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company.
Brokers have set a 12 month consensus price objective of $16.75 for the company and are forecasting that the company will post ($0.63) earnings per share for the current quarter, according to Zacks. Zacks has also given Trevi Therapeutics an industry rank of 73 out of 256 based on the ratings given to related companies.
A number of research analysts recently issued reports on TRVI shares. Stifel Nicolaus started coverage on Trevi Therapeutics in a report on Monday, June 3rd. They issued a “buy” rating and a $20.00 price target for the company. Leerink Swann started coverage on Trevi Therapeutics in a report on Monday, June 3rd. They issued an “outperform” rating for the company. BMO Capital Markets started coverage on Trevi Therapeutics in a report on Monday, June 3rd. They issued an “outperform” rating and a $15.00 price target for the company. Needham & Company LLC assumed coverage on Trevi Therapeutics in a report on Monday, June 3rd. They issued a “buy” rating and a $18.00 price target for the company. Finally, Svb Leerink began coverage on Trevi Therapeutics in a research report on Monday, June 3rd. They set an “outperform” rating and a $14.00 target price for the company.
Shares of NASDAQ TRVI opened at $7.95 on Monday. Trevi Therapeutics has a 52-week low of $7.18 and a 52-week high of $10.62.
Trevi Therapeutics Company Profile
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.
Featured Story: Cost of Debt
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.